The latest issues of two American Psychiatric Association journals, The American Journal of Psychiatry and Psychiatric Services, are now available online.

Stifel initiates Compass Pathways with a buy, highlighting psychedelics' therapeutic potential. Read more here.

Jason Najum talks to Srinivas Rao, CEO of Atai Life Sciences, a biotech company focused on mental health and psychedelic compounds.

Treatment-resistant depression complicates care, defying standard treatments, but new therapies are on the horizon, offering hope for more effective treatment options.

Ketamine, a dissociative anesthetic, has carved itself a spot in the world of mental health care over the past two decades.

China: A recent randomized clinical trial has highlighted the potential benefits of intraoperative esketamine in reducing ...

Intraoperative esketamine infusion significantly reduced the incidence of postpartum depression (PPD) at 6 weeks post partum ...

The American Psychiatric Association (APA) named Mark Rapaport, MD, of the University of Utah, as the medical society's next ...

Major depressive disorder (MDD) is a leading cause of disability worldwide, with a significant proportion of patients (10-20%) progressing to treatment-resistant depression (TRD).

The company announced on 18 February that the trial did not meet its primary endpoint measured by a depression rating scale, ...

IntroductionMajor depressive disorder (MDD) is a leading cause of disability worldwide, with a significant proportion of patients (10-20%) progressing ...

Ketamine, a non-competitive N-methyl-D-aspartate receptor antagonist, has emerged as an effective therapeutic agent for the management of treatment-resistant depression. Repeated treatments with ...